Curis (CRIS)
(Delayed Data from NSDQ)
$16.36 USD
-0.15 (-0.91%)
Updated May 3, 2024 04:00 PM ET
After-Market: $16.67 +0.31 (1.89%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth F Momentum F VGM
Brokerage Reports
Curis, Inc. [CRIS]
Reports for Purchase
Showing records 261 - 280 ( 302 total )
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
Late Breaking Data - Chances of Positive Pivotal Trial Results Just Increased
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
Late Breaking Data - Chances of Positive Pivotal Trial Results Just Increased
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
Life Sciences - Highlights from JP Morgan - Key 2011 Drivers for Several Companies Under Coverage.
Provider: RODMAN & RENSHAW, CO.
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
Life Sciences: Highlights from JP Morgan - Key 2011 Drivers for Several Companies Under Coverage.
Provider: RODMAN & RENSHAW, CO.
Analyst: NOCHOMOVITZ Y
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
R&Rs Week in Review: Oncology and Stem Cell Sectors
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
2010 RECAP & 2011 PREVIEW
Provider: RODMAN & RENSHAW, CO.
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
Pipeline Enhanced With Selection of Dual Pi3K/HDAC Inhibitor for Clinical Development
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
Pipeline Enhanced With Selection of Dual Pi3K/HDAC Inhibitor for Clinical Development
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
R&Rs Week in Review: Oncology and Stem Cell Sectors
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
Highlights from Meeting with Management -Progress on Partnered and Proprietary Fronts
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
3Q10 UPDATE -GDC-0449 POISED FOR SUCCESS IN MUTATION-DRIVEN BCC
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.